抄録
In most H. pylori-positive patients, gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas regress both endoscopically and histopathologically after H. pylori eradication, but no factors that can be predictive of the response to the eradication have been definitively identified, and there is little information on how to determine the optimal observation period before additional treatment can be started. Here, clinical studies dealing with the diagnosis and treatment of gastric MALT lymphomas and H. pylori published during the last 5 years were systematically reviewed, and studies identifying the molecular approaches involved in the pathogenesis were summarized. Most of the clinical studies indicate a favorable effect of H. pylori eradication on the clinical outcome of gastric MALT lymphomas. Some studies suggest the necessity of additional treatment in nonresponders to H. pylori eradication, while others suggest the adoption of a watch-and-wait strategy. The molecular characteristics of MALT lymphomas could play an important role in prognostic prediction and the selection of further therapeutic intervention after the eradication. This updated review of gastric MALT lymphomas illustrates the potential efficacy of H. pylori eradication in tumor remission, but further molecular characterization is necessary to establish the most suitable therapeutic strategy for patients who do not respond to eradication.
| 元の言語 | English |
|---|---|
| ページ（範囲） | 81-87 |
| ページ数 | 7 |
| ジャーナル | Gut and Liver |
| 巻 | 3 |
| 発行部数 | 2 |
| DOI | |
| 出版物ステータス | Published - 2009 6 |
Fingerprint
ASJC Scopus subject areas
- Gastroenterology
- Hepatology
これを引用
Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma : Updated review of clinical outcomes and the molecular pathogenesis. / Suzuki, Hidekazu; Saito, Yoshimasa; Hibi, Toshifumi.
：: Gut and Liver, 巻 3, 番号 2, 06.2009, p. 81-87.研究成果: Article
}
TY - JOUR
T1 - Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma
T2 - Updated review of clinical outcomes and the molecular pathogenesis
AU - Suzuki, Hidekazu
AU - Saito, Yoshimasa
AU - Hibi, Toshifumi
PY - 2009/6
Y1 - 2009/6
N2 - In most H. pylori-positive patients, gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas regress both endoscopically and histopathologically after H. pylori eradication, but no factors that can be predictive of the response to the eradication have been definitively identified, and there is little information on how to determine the optimal observation period before additional treatment can be started. Here, clinical studies dealing with the diagnosis and treatment of gastric MALT lymphomas and H. pylori published during the last 5 years were systematically reviewed, and studies identifying the molecular approaches involved in the pathogenesis were summarized. Most of the clinical studies indicate a favorable effect of H. pylori eradication on the clinical outcome of gastric MALT lymphomas. Some studies suggest the necessity of additional treatment in nonresponders to H. pylori eradication, while others suggest the adoption of a watch-and-wait strategy. The molecular characteristics of MALT lymphomas could play an important role in prognostic prediction and the selection of further therapeutic intervention after the eradication. This updated review of gastric MALT lymphomas illustrates the potential efficacy of H. pylori eradication in tumor remission, but further molecular characterization is necessary to establish the most suitable therapeutic strategy for patients who do not respond to eradication.
AB - In most H. pylori-positive patients, gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas regress both endoscopically and histopathologically after H. pylori eradication, but no factors that can be predictive of the response to the eradication have been definitively identified, and there is little information on how to determine the optimal observation period before additional treatment can be started. Here, clinical studies dealing with the diagnosis and treatment of gastric MALT lymphomas and H. pylori published during the last 5 years were systematically reviewed, and studies identifying the molecular approaches involved in the pathogenesis were summarized. Most of the clinical studies indicate a favorable effect of H. pylori eradication on the clinical outcome of gastric MALT lymphomas. Some studies suggest the necessity of additional treatment in nonresponders to H. pylori eradication, while others suggest the adoption of a watch-and-wait strategy. The molecular characteristics of MALT lymphomas could play an important role in prognostic prediction and the selection of further therapeutic intervention after the eradication. This updated review of gastric MALT lymphomas illustrates the potential efficacy of H. pylori eradication in tumor remission, but further molecular characterization is necessary to establish the most suitable therapeutic strategy for patients who do not respond to eradication.
KW - API2-MALT1 fusion
KW - BCL10
KW - CD20
KW - Eradication
KW - Helicobacter pylori
UR - http://www.scopus.com/inward/record.url?scp=67649289709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649289709&partnerID=8YFLogxK
U2 - 10.5009/gnl.2009.3.2.81
DO - 10.5009/gnl.2009.3.2.81
M3 - Article
C2 - 20431728
AN - SCOPUS:67649289709
VL - 3
SP - 81
EP - 87
JO - Gut and Liver
JF - Gut and Liver
SN - 1976-2283
IS - 2
ER -